Cassava Sciences, Inc. - SAVA STOCK NEWS

Cassava Sciences (Nasdaq: SAVA) is set to present new clinical data for its Alzheimer's candidates, SavaDx and simufilam, at the 2021 Alzheimer’s Association International Conference in Denver from July 26-30. A poster presentation on July 26 will detail SavaDx, while an oral presentation on July 29 will cover interim safety and cognitive results from the first 50 patients in a 9-month trial of simufilam. Key biomarkers will also be presented, crucial for understanding the drugs' mechanisms of action and potential in Alzheimer's treatment.

Cassava Sciences has appointed Premier Research International as its clinical research organization to lead the Phase 3 clinical program for simufilam, aimed at treating Alzheimer's disease. The company plans to initiate this pivotal program in the second half of 2021. With extensive experience in neuroscience, Premier Research will support Cassava in advancing simufilam into critical testing phases. This collaboration marks a significant step forward for Cassava as it seeks to address the pressing need for effective Alzheimer's therapies.

Cassava Sciences, Inc. (Nasdaq: SAVA) announced significant progress in its clinical development of simufilam for Alzheimer's disease. The open-label study successfully enrolled 150 subjects, and results from interim analyses will be presented at the Alzheimer's Association International Conference (AAIC) in July. The Cognition Maintenance Study has commenced with a 30% enrollment rate. Cassava plans to initiate a Phase 3 program in the latter half of 2021, supported by around $282 million in cash. The ongoing research is backed by NIH grants, emphasizing the company's commitment to developing innovative treatments.

Cassava Sciences (Nasdaq: SAVA) announced its participation in the Raymond James 2021 Human Health Innovation Conference. The virtual event is scheduled for June 21-23, 2021.

Management, including President & CEO Remi Barbier and CFO Eric Schoen, will deliver a corporate overview on June 22 at 3:20 PM ET. They will also engage with institutional investors throughout the conference. A replay of the presentation will be accessible until September 20, 2021 on the company's website under the ‘Investors’ tab.

Cassava Sciences, Inc. (Nasdaq: SAVA) announced the appointment of Mr. Richard Barry to its Board of Directors as of June 11, 2021. Mr. Barry, an experienced investor and former managing partner at Eastbourne Capital Management, will provide insights on sustainability and governance. His appointment aims to bolster the company's commitment to societal goals while progressing towards a Phase 3 clinical program for Alzheimer’s disease. Mr. Barry holds 150,000 shares of SAVA, underscoring his confidence in the company’s mission.

Cassava Sciences (Nasdaq: SAVA) is set to join a virtual panel on innovative treatment approaches for Alzheimer’s disease on May 26 at 11:00am Eastern Time. The discussion will be moderated by Jason McCarthy, PhD, from Maxim Group, featuring Remi Barbier, President & CEO of Cassava Sciences. Alzheimer's, affecting approximately 50 million people globally, is a progressive brain disorder without current drug therapies to halt its advancement. The annual global cost of dementia exceeds $1 trillion.

Cassava Sciences has secured a $2.7 million research grant from the National Institutes of Health (NIH) to fund clinical readiness activities for its Phase 3 program with simufilam, a drug candidate targeting Alzheimer's disease. This grant follows a peer review process which validated the clinical and scientific data of simufilam. The company aims to leverage this funding to advance its commitment to developing effective treatments for Alzheimer’s, as the global dementia cost surpasses $1 trillion

Cassava Sciences, a biotechnology company focused on Alzheimer’s disease, has initiated a Cognition Maintenance Study (CMS) to assess the effects of simufilam in patients with the condition. The randomized, controlled study aims to enroll 100 participants and evaluate cognitive changes over six months between those who continue and discontinue treatment. Simufilam targets neurodegeneration and inflammation, and early results have shown positive cognitive outcomes. The study is part of the company’s broader strategy to advance simufilam towards Phase 3 trials.

Cassava Sciences, Inc. (Nasdaq: SAVA) will participate in the B. Riley Securities’ Neuroscience Conference on April 28-29, 2021. Remi Barbier, President & CEO, is set to engage in a virtual Fireside Chat on April 28 at 2:30 PM Eastern. The conference will address topics in neurodegeneration and neuropsychiatry, featuring prominent companies in the field. An archived replay of the chat will be available on Cassava's website for about 90 days post-event. For details, visit CassavaSciences.com.